JPRN-jRCT2071230052招募中1 期
Phase I study to investigate the pharmacokinetics, food effect, and safety of AKP-009 after single and multiple oral doses
Shimomiya Kazuhiro0 个研究点目标入组 81 人开始时间: 2023年8月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- Male
入选标准
- •Individuals who are capable of understanding the nature of the study and can provide written voluntary consent to participate in the study
- •- Healthy adult Japanese men 65 to 85 years of age (inclusive) at the time of informed consent for the multiple-dose 20 mg-H group, and healthy adult Japanese men 20 to 40 years of age (inclusive) at the time of informed consent for the other groups
- •- Individuals with a BMI of >= 18.5 and <= 25.0 at screening
排除标准
- •- Individuals with current or previous disease considered inappropriate for participation in the study, such as liver disorders, kidney disorders, cerebrovascular/cardiovascular disorders, gastrointestinal disorders, blood diseases, or endocrine diseases
- •- Individuals with drug allergy
- •- Individuals with current or previous convulsive disorder such as epilepsy
- •- Individuals with current or previous alcoholism
- •- Individuals who test positive for drug abuse at screening
- •- Individuals who test positive for HBs antigen, HCV antibody, HIV antigen/antibody, or serological syphilis at screening
- •- Individuals who weigh less than 50 kg at screening
- •- Individuals from whom at least 200 mL or 400 mL of blood had been collected within 4 or 12 weeks before study treatment, respectively, or who had donated blood component within 2 weeks before study treatment
- •- Individuals who are considered by the investigator/subinvestigator to be unsuitable for participation in the study based on the medication status within 1 week before study treatment
- •- Individuals who had participated in another clinical trial within 16 weeks before study treatment
研究者
相似试验
进行中（未招募）
1 期
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 18.1 Level: PT Classification code 10011762 Term: Cystic fibrosis System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-004302-26-GBSanten Oy18
进行中（未招募）
1 期
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-004302-26-SKSanten Oy18
进行中（未招募）
1 期
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-004302-26-HUSanten Oy18
进行中（未招募）
1 期
Study of how tafluprost is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure. Tolerance to the drug and safety in general will also be assessed.Glaucoma or Ocular HypertensionMedDRA version: 20.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2013-004302-26-PLSanten Oy18
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38